WebJan 10, 2024 · Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement … WebApr 14, 2024 · Chicago, April 14, 2024 (GLOBE NEWSWIRE) -- The global Crypto Asset Management Market size is projected to grow from USD 0.4 billion in 2024 to USD 1.2 billion by 2026, at a Compound Annual Growth ...
2024-08-10 NDAQ:IRON Press Release Disc Medicine Inc.
WebDec 29, 2024 · Gemini Therapeutics, Inc. (GMTX) has announced a 1-for-10 reverse stock split, and a name, symbol, and CUSIP change, in conjunction with a reverse merger with Disc Medicine, Inc. As a result, each GMTX Common Share will be converted into the right to receive 0.10 (New) Disc Medicine, Inc. (IRON) Common WebOn January 10, 2024, Gemini Therapeutics, Inc. (the “Company”) announced that the Company will discontinue both of its ongoing Phase 2a clinical trials, the ReGAtta study … lightly fried tofu
Gemini Therapeutics Provides GEM103 Program Update
WebJul 28, 2024 · Gemini Therapeutics, Inc. (NASDAQ:GMTX) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund … WebFounded Date 2015. Founders James McLaughlin. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Gemini Therapeutics, Inc. Stock Symbol … WebApr 11, 2024 · Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic PRESS RELEASE PR Newswire Apr. 11, 2024, 07:00 AM lightly kde manjaro